264 related articles for article (PubMed ID: 27169668)
1. Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.
Henke H; Kryeziu K; Banfić J; Theiner S; Körner W; Brüggemann O; Berger W; Keppler BK; Heffeter P; Teasdale I
Macromol Biosci; 2016 Aug; 16(8):1239-1249. PubMed ID: 27169668
[TBL] [Abstract][Full Text] [Related]
2. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
Gibson D
ChemMedChem; 2021 Jul; 16(14):2188-2191. PubMed ID: 33928760
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates.
Hackl CM; Schoenhacker-Alte B; Klose MHM; Henke H; Legina MS; Jakupec MA; Berger W; Keppler BK; Brüggemann O; Teasdale I; Heffeter P; Kandioller W
Dalton Trans; 2017 Sep; 46(36):12114-12124. PubMed ID: 28862707
[TBL] [Abstract][Full Text] [Related]
5. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
6. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
7. Vitamin B₁₂ as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies.
Ruiz-Sánchez P; König C; Ferrari S; Alberto R
J Biol Inorg Chem; 2011 Jan; 16(1):33-44. PubMed ID: 20803225
[TBL] [Abstract][Full Text] [Related]
8. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
Johnstone TC; Suntharalingam K; Lippard SJ
Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
[TBL] [Abstract][Full Text] [Related]
9. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
10.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
11. Novel synthesis of platinum complexes and their intracellular delivery to tumor cells by means of magnetic nanoparticles.
Quarta A; Amorín M; Aldegunde MJ; Blasi L; Ragusa A; Nitti S; Pugliese G; Gigli G; Granja JR; Pellegrino T
Nanoscale; 2019 Dec; 11(48):23482-23497. PubMed ID: 31808496
[TBL] [Abstract][Full Text] [Related]
12. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
13. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
14. Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential.
Leal J; Santos L; Fernández-Aroca DM; Cuevas JV; Martínez MA; Massaguer A; Jalón FA; Ruiz-Hidalgo MJ; Sánchez-Prieto R; Rodríguez AM; Castañeda G; Durá G; Carrión MC; Barrabés S; Manzano BR
J Inorg Biochem; 2021 May; 218():111403. PubMed ID: 33730639
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.
Thiabaud G; He G; Sen S; Shelton KA; Baze WB; Segura L; Alaniz J; Munoz Macias R; Lyness G; Watts AB; Kim HM; Lee H; Cho MY; Hong KS; Finch R; Siddik ZH; Arambula JF; Sessler JL
Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7021-7029. PubMed ID: 32179677
[TBL] [Abstract][Full Text] [Related]
16. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
17. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands.
Margiotta N; Savino S; Marzano C; Pacifico C; Hoeschele JD; Gandin V; Natile G
J Inorg Biochem; 2016 Jul; 160():85-93. PubMed ID: 26775068
[TBL] [Abstract][Full Text] [Related]
19. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
20. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
